Halozyme Therapeutics, Inc. · NASDAQ:HALO
Posard Matthew L. sold 5,230 Halozyme Therapeutics, Inc. shares (Form 4)
Traded Oct 1, 2026 · Filed Oct 2, 2026
On Oct 1, 2026, Posard Matthew L. (Director) sold 5,230 Halozyme Therapeutics, Inc. shares at an average US$108.54 for US$568K under a trading plan, leaving 53,609 shares. Filed Oct 2, 2026 (Form 4).
- Sold
- 5,230 shares
- Price
- US$108.54 average (US$107.17 to US$110.04)
- Value
- US$568K
- Holding after
- 53,609 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Director
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | Common Stock | Sale | 730 | US$107.17 | 58,109 | Direct |
| Oct 1, 2026 | Common Stock | Sale | 3,300 | US$108.45 | 54,809 | Direct |
| Oct 1, 2026 | Common Stock | Sale | 1,100 | US$109.57 | 53,709 | Direct |
| Oct 1, 2026 | Common Stock | Sale | 100 | US$110.04 | 53,609 | Direct |
Source
Related
- Halozyme Therapeutics, Inc.
- Posard Matthew L.
- Halozyme Therapeutics, Inc. shareholders
- Form 4 · Posard Matthew L. · Sep 17, 2026
- Form 4 · Posard Matthew L. · May 7, 2026
- Form 4 · Torley Helen · Oct 8, 2026
- Form 4 · Daly James M · Oct 2, 2026
- Form 4 · Torley Helen · Sep 11, 2026
- Form 4 · Appelhans Dannielle · Sep 2, 2026
- Form 4 · Torley Helen · Aug 19, 2026